secwatch / observer
8-K filed July 11, 2023, 7:59 PM ET ticker RMTI CIK 0001041024
M&A confidence high sentiment positive materiality 0.80

Rockwell Medical acquires Evoqua hemodialysis concentrates business for $16M total consideration

ROCKWELL MEDICAL, INC.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

ROCKWELL MEDICAL, INC. reported 2023 results: revenue between $82.0 million and $86.0 million. Guidance raised.

Period
2023
Revenue
between $82.0 million and $86.0 million
Guidance
raised
Result
guidance update
Exact text from the filing
Rockwell Medical increases its 2023 revenue guidance to between $82.0 million and $86.0 million.
View on SEC.gov
Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

ROCKWELL MEDICAL, INC. entered into Asset Purchase Agreement with Evoqua Water Technologies LLC valued at $11,000,000 in cash paid at Closing and equal annual installments of $2,500,000 (effective 2023-07-10).

Action
entry
Agreement
asset purchase
Counterparty
Evoqua Water Technologies LLC
Value
$11,000,000 in cash paid at Closing and equal annual installments of $2,500,000
Effective
2023-07-10
Exact text from the filing
On July 10, 2023, Rockwell Medical, Inc. (the “Company”) executed and consummated the transactions contemplated by an Asset Purchase Agreement (the “Purchase Agreement”) with Evoqua Water Technologies LLC, a Delaware limited liability company (“Evoqua”).
View on SEC.gov
Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

ROCKWELL MEDICAL, INC. entered into Letter Agreement with Armistice Capital Master Fund Ltd. valued at approximately $13.8 million (effective 2023-07-10).

Action
entry
Agreement
equity purchase
Counterparty
Armistice Capital Master Fund Ltd.
Value
approximately $13.8 million
Effective
2023-07-10
Exact text from the filing
On July 10, 2023, the Company entered into a letter agreement (the “Letter Agreement”) with Armistice Capital Master Fund Ltd. (“Armistice”), which held a warrant (the “Prior Warrant”) to purchase 9,900,990 shares of common stock of the Company (the “Common Stock”) with an exercise price of $1.39 per share, offering Armistice the opportunity to exercise the Prior Warrant for cash, provided the Prior Warrant was exercised for cash on or prior to 5:00 P.M. Eastern Time on July 10, 2028 (the “End Date”).
View on SEC.gov

Browse all earnings releases →

ROCKWELL MEDICAL, INC. filing history →

Source: SEC EDGAR
accession 0001104659-23-079774
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.